References
- Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animal model. Cancer 1977; 39: 1357–1361
- Hayes D M, Cvitkovic E, Golbey R B, et al. High dose cisplatinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372–1381
- Ostrow S, Egurin M J, Hahn D, et al. High-dose cisplatin therapy using mannitol versus furosemide diuresis: Comparative pharmacokinetics and toxicity. Cancer Treat Rep 1981; 65: 73–78
- Rossof A H, Slayton R E, Perlia C P. Preliminary clinical experience with cis-diamminedichloro-platinum (II) (NSC 119875, CACP). Cancer 1972; 30: 1451–1456
- Lippman A J, Helson C, Helson L, et al. Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother Rep 1973; 57: 191–200
- Piel I J, Meyer D, Perlia C P, et al. Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep 1974; 58: 871–875
- Aguilar-Markulis N V, Beckley S, Priore R, et al. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol 1981; 16: 111–123
- Reddel R R, Kefford R T, Grant J M, et al. Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treat Rep 1982; 66: 19–23
- Vermorken J B, Kapteijn T S, Hart A A, et al. Ototoxicity of cis-diamminedichloroplatinum (II) influence of dose, schedule and mode of administration. Eur J Clin Oncol 1983; 19: 53–58
- Laurell G, Borg E. Ototoxicity of cisplatin in gynaecological cancer patients. Scand Audiol 1988; 17: 241–247
- Stadnicki S W, Fleischmann R, Schaeppi U, et al. Cis-dichlorodiammineplatinum (II) (NSC-119875). Hearing loss and other toxic effects in Rhesus monkeys. Cancer Chemother Rep 1975; 5: 467–480
- Fleischman R W, Stadnicki S W, Ethier M F, et al. Ototoxicity of cis-dichlorodiammine platinum (II) in the guinea pig. Toxicol Appl Pharmacol 1975; 33: 320–332
- Estrem S A, Babin R W, Ryu J H, et al. Cis-diam-minedichloroplatinum (II) ototoxicity in the guinea pig. Otolaryngol Head Neck Surg 1981; 89: 638–645
- Komune S, Asakuma A, Snow J B. Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum. Otolaryngol Head Neck Surg 1981; 89: 275–282
- Tange R A, Vuzevski V D. Changes in the stria vascularis of the guinea pig due to cis-platinum. Arch Otorhinolaryngol 1984; 239: 41–47
- Schweitzer V G, Rarey K E, Dolon D F, et al. Ototoxicity of cisplatin vs. platinum analogs CDDCA (JM-8) and CHIP (JM-9). Presented at the AAOARO research Forum, Las Vegas, September. 1984
- Barron S E, Daigneault E A. Effect of cisplatin on hair cell morphology and lateral wall Na, K-ATPase activity. Hear Res 1987; 26: 131–137
- van Zeijl L GPM, Conijn E AJG, Rodenburg M, et al. Analysis of hearing loss due to cis-diamminedichloroplatinum-II. Arch Otorhinolaryngol 1984; 239: 255–262
- Brown R, Nuss R, Pattersson R M, et al. Audiometric monitoring of cis-platinum ototoxicity. Gynecol Oncol 1983; 16: 254–262
- Fausti S A, Schechter M A, Rappaport B Z, et al. Early detection of cisplatin ototoxicity. Cancer 1984; 53: 224–231
- Dreschler W A, van den Hulst R JAM, Tange R A, et al. The role of high-frequency audiometry in early detection of ototoxicity. Audiology 1985; 24: 387–395
- Tange R A, Dreschler W A, van den Hulst R JAM. The importance of high-tone audiometry in monitoring for ototoxicity. Arch Otorhinolaryngol 1985; 242: 77–81
- Laurell G, Jungnelius U. High dose cisplatin treatment. Hearing loss and plasma concentration. Laryngoscope, in press
- Kedar A, Cohen M E, Freeman A I. Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum (II) treatment: A case report. Cancer Treat 1978; 62: 819–821
- Hadley D, Herr H W. Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment. Cancer 1979; 44: 2026–2028
- Thompson S W, Davis L E, Kornfeld M, et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic and toxicologic studies. Cancer 1984; 54: 1269–1275
- Anderson H, Barr B, Wedenberg E. Intra-aural reflexes in retrocochlear lesions. 10th Nobel Symp: Disorders of the Skullbase Region, Stockholm, August 1968; 1969: 49–55, p.
- Thomsen J, Terkildsen K. Audiological findings in 125 cases of acoustic neuromas. Acta Otolaryngol (Stockh) 1975; 80: 353–361
- Silman S, Gelfand S A, Piper N, . Prediction of hearing loss from the acoustic-reflex threshold;. The Acoustic Reflex, Basic Principles and Clinical Application, S Silman, et al. Academic Press, Orlando 1984; 187–197
- Engström B, Borg E. Cochlear morphology in relation to loss of behavioural, electrophysiological, and middle-ear reflex thresholds after exposure to noise. Acta Otolaryngol [suppl] (Stockh) 1983; 402: 1–23
- Anderson H, Wedenberg E. Audiometric identification of normal hearing carriers of genes for deafness. Acta Otolaryngol (Stockh) 1968; 65: 535–554
- Hirsch A, Anderson H. Elevated stapedius reflex threshold and pathologic reflex decay. Acta Otolaryngol [suppl] (Stockh) 1980; 368: 1–28
- Jervall L, Dryselius H, Arlinger S. Comparison of manual and computer-controlled audiometry using identical procedures. Scand Audiol 1983; 12: 209–213
- Laurell G, Engström B. The ototoxic effect of cisplatin on guinea pigs in relation to dosage. Hearing Res 1989; 38: 27–34
- Moroso M J. Genetic disposition to deafness in maternal rubella: Fact or myth?. J Otolaryngol 1985; 14: 44–48